Monitor for any conversion of this 13G to a 13D, which would signal activist intent. The passive stake is routine and does not indicate a change in investment thesis.
XENE drugs
XENE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5- T+0 · Nov 5 $37.68entry
- T+1 · 11d ago +3.95%α +3.64% · $39.17
- T+5 · 5d ago +8.80%α +5.51% · $41.00
- T+7 · todayOpen
- T+20 · in 17d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
FMR LLC (Fidelity) filed an amended Schedule 13G reporting beneficial ownership of 11,136,649 shares of Xenon Pharmaceuticals Inc. as of September 30, 2026, representing 11.5% of outstanding common stock. This is a routine quarterly update by a passive institutional investor; the stake level is consistent with prior filings.
Key Financial Metrics
Key Facts
- FMR LLC reported beneficial ownership of 11,136,649 shares of Xenon Pharmaceuticals common stock as of September 30, 2026.
- The stake represents 11.5% of outstanding shares.
- The filing is an amendment to Schedule 13G, indicating passive investment intent.
- Fidelity Management & Research Company LLC beneficially owns 5% or greater of the outstanding shares.
Financial Impact
FMR LLC holds 11.5% of Xenon Pharmaceuticals, valued at approximately $425.5 million based on the $3.7B market cap.
Risk Factors
- No material risks identified from this routine passive stake filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000315066-26-002888 |
| Document: 0000315066-26-002888-index-headers.html | 0000315066-26-002888 |
| Document: 0000315066-26-002888-index.html | 0000315066-26-002888 |
| Document: 0000315066-26-002888.txt | 0000315066-26-002888 |
Track record
19 reports on XENE
3 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +18.60% at T+60 after the Apr 19, 2026 report. 4 of 5 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $40.11 Now $39.26 −2.12% settles Nov 17
- Nov 9, 20267d ago 8-K Neutral 5/10 Entry $41.39 to $42.10 Now $39.26 −5.15% ▲ +1.72% +0.40% vs SPY
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 6, 202610d ago SC 13G Neutral 4/10 Entry $39.17 to $40.45 Now $39.26 +0.23% ▲ +3.27% +0.90% vs SPY
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Viewing Entry $37.68 to $39.17 Now $39.26 +4.19% ▲ +3.95% +3.64% vs SPY
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $39.19 to $37.68 Now $39.26 +0.18% ▼ −3.85% +0.56% vs SPY
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $38.23 to $39.19 Now $39.26 +2.69% ▲ +2.51% +0.86% vs SPY
- Oct 1, 20266w ago Insider Cluster Bullish 6/10 Entry $38.93 to $38.02 Now $39.26 +0.85% ▼ −2.34% −3.08% vs SPY
- Jul 2, 202619w ago Press Release Neutral 1/10 Entry $60.96 to $60.54 Now $39.26 −35.60% ▼ −0.69% −1.56% vs SPY
- Jun 5, 202623w ago 144 Neutral 2/10 Entry $51.21 to $52.79 Now $39.26 −23.34% ▲ +3.09% +3.38% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers